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Abstract
A case qfStevens-]ohnson Syndrome (SJ S) induced bycarbamarepi ne in a psychiatricpatient
with schieo-offec tioe disorder is reported. Th e pat ient also had diabetes mellitu s and was on
glyburide which posed an initial dilemma at the onset qfSJS as to the causati ve drug. In view ofthe
expanding use qfcarbamazep ine in psychiat ric patients and the potent ially lethal consequences cf
SJS, the autho rs suggest a risk management approach when initiating Carbamazepine therapy to
reduce the incidence and morbidity ofthe syndrome.
Among the adve rse dermatologi c manifest ations associa te d wit h d ru g the rapy,
Ste ve ns -j ohns on Synd ro me (SjS) st ands ou t as a se vere, pot ent iall y lethal adve rse
effec t. SjS has been associated with th e us e of ca rba maze pine a nd a lso phen ob arb ita l
and phen ytoin, most ly in neurological cases. It is of inte rest to not e th at in th e case of
ca rba m aze pine, th e first su ch described case occurred in th e year it was int roduced
(I) . The overall inciden ce from studies of ca rba maze pine -induced SjS is low (an
average of about 5 per 1,000,000 ca se s) and is co ns ide re d un common (2 ,3,4).
C arbamazepine is an iminodibenzyl derivative with a structure sim ilar to th e t ricyclic
antidepressants. In clin ica l neurology , ca rba maze pine has been effec t ive in th e
treatment of psychomotor and grand m al se izu re s, as well as trigeminal ne u ralgia.
SjS is a clinical syndrome presum ed to be a hypersen sitivity reacti on m a nifest ed
initia lly with prodromal symptoms offever, malaise and a sore throat. T he pro d romal
phase is then fo llowed in some days (up to 14 days) by an ac u te poly morph ous
dermatologic synd rome manifest ed as e ryt he matous m acul o-papular like lesions,
target lesions , bullae, vesicles, involvement of a t least two mucou s membranes,
conj u nc tivitis and an associated syst emic toxic state.
Sin ce the japanese (5) postulated and described th e possibl e effec t ive ne ss of
ca rba m aze pine in affective disorders and the subsequent con firmat ion of thi s in lat e r
controlled clinica l trials (6), ca rbam aze pine has been incr easingly used by psychia-
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trist s as a mood st abilizer. Alon g with th e increasing use of carbamazepine in
con te m porary psychi at ric practice is the rare occ urre nce of SJS as a sid e effec t.
H owever, very few cases have been d escribed in the psychi a t ric lite ra tu re so far (7).
W e present a case of ca rbamazepine-associa te d SJS in a psyc hiat r ic patient wh o a lso
had diabet es m ellitus and was a lso on treatment with glybu r ide in our institution .
CASE REPORT
A thirty-five year old ca ucasia n mal e, single, domiciled , unemployed , coll eg e educa te d
wit h a greater than 15 years psychi atric hist ory a nd multiple past psychi atric ad m issions,
treated in th e past wit h hal operidol and lithium was ad m itted to our institution on February 6,
1994, with a lon g diagn osis of sc hizoaffect ive d isorder. On ad mission , a long with paranoid a nd
gra nd iose delusion s, the patient a lso had a pronounced manic state . H e was start ed on
halop eridol, lithium and ben ztropine. Since he also su ffere d fro m ad ult onset diabet es mell itu s
(d iagnosed in a not he r institution a year ag o prio r to this adm ission) , an d was on trea t men t
with regular insulin as a n ou tpa tien t, thi s was co nt inue d .
On adm ission, t he pat ient had fluctuating mildly incr eased blood suga r levels, for which
th e unit int ernist pr escribed glyburide while th e patient was weaned off insul in . G lyburide was
star te d eight days after ad m ission . Fro m the past hist ory th e pat ient was not com plia nt with
lithiu m therapy an d this was a lso confi rmed up on admission when he refused to tak e lithi um .
He subseque nt ly rep ort ed t hat he was non -complian t on lithiu m because of a fixed idea th at his
sis ter was co lla borati ng wit h his th e rapist to label him a bipolar in order to disqualify him from
a fa mi ly inherit ance.
As the pat ien t's manic syndrome continued, an a lternative mood st abilizer was so ug ht.
Carbamazepine was found acceptable to t he patient as a substitut e for lithiu m ten days after
admission. Carbamazepine was begun and t itra ted upwa rds. T en days afte r initiation of
ca rba maze pine therapy, t he patient d eveloped flu- like symptoms with a sore throat. Two days
lat e r, he developed dermato log ic lesions consisti ng prin cipally of an eryt he ma to us maculpapu-
la r rash. G lyburide was d iscont inued as this react ion was th ought to have been ca used by th e
med ica tion . A slid ing sca le regular insu lin coverage regimen was ins titut ed in place of
glybu rid e, wh ile th e pat ient re ma ined on halop eridol and ca rbamazepine. In addition , ora l
pr ed nisone 40 mg was add ed to t he t reatmen t.
Th ree days a fter the appearance of th e flu- like symptoms and dermatologic rash , th e
derma tol ogy co ns ultan t d iagn osed drug-induced morbilli for m eru pt ion secondary to gly-
buride. The dermat ologist reco m mende d cont inued t rea t me nt with oral pr ednisone, whil e
add ing tr iamcin olon e for dermal applicat ion. However, t he pat ien t's dermal eru pt ion got
worse, and he develop ed bleeding intranasal lesion s, ulcera ti ng buccal lesion s, incr eas ed
mal ai se , a nd ge neralized bodil y aches and discomfort. He mat ological a nd blood che m istry
work up results were within normal limit s. T wo days from t he firs t dermatologic consu lt, a
sus picion of possibl e SJS was rai sed and a second derma tology consu lt was sought. At thi s ti me,
th e pa t ient was feb ril e ( 100 F) and because of th e oral lesion s had difficulty ea t ing. Review of
th e case by th e se nior d erma tologist led to diagnosis of SJS attribut ed to ca rba maze pine . (Two
days before the ini tia l dermal e ru ption, t he serum ca rba maze pine level was 8.4 f.l.g/ml ; two
days after the eruption se rum carbarnazepine level measured 9.3 f.l.g /ml) . Carbamazepine was
dis co ntinued im media tely and because of the worse ning physica l cond it ion of the patient , a
decision was made to transfer t he patient to the medica l floor.
T rea t ment on th e medical floor consisted of ha loperidol, oral pr ednisone and a sliding
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scale insulin coverage regim en. Seven days from the beginnin g of the flu-like symptom s, the
int ermittent nasal bleedin g subsided, the feeling of malaise was reduced, and oral lesions
sta rted showing signs of remission. Th e pati ent 's manic symptoms, along with the delusions ,
had now almost resolved. Pati ent was discharged home from the medicine unit thirty-two days
afte r his initial psychiatric admission with plans for follow up in the outpatient psychiatry and
medicine clinics. A suggestion was also mad e for a trial with valproic acid as a mood stabi lizer.
DISCUSSION AND COMMENTARY
A sma ll number of psychotropics have been associat ed with SJS, fr equently cited
are ph enobarbital , ph enytoin, fluoxitine , meprobamat e a nd ca rba mazepine (8,9). In
the psychiatry literature , ca rba m aze pine-assoc ia te d SJS has been rare. The first such
described case was reported in the United States ( 10) th e mo st recent cas e was
report ed from Canada (II) .
Considering the potentially lethal consequen ces of SJS a nd th e incr easin g use of
ca rba ma ze pine in psychiatry (not only as a mood st abilizer, but a lso for oth er
psychiatric indications including impulse control and alc oh ol detoxification ) (12) ,
cont inue d us e of ca rba m aze pine should be considered agains t the ba ck grou nd of
cu r re nt th erapeutic information. Som e authors have sug ges te d an increased r isk of
SJS wh en neuroleptics are com bine d with ca rba maze pine (13) . Others have recom-
m ended patch testing prospective recipi ents for hypersensitivit y to the d rug (14) .
This sho uld, however, be done havin g in mind the risk of a fal se posi tive test result
a nd a n occasional unpleas ant derm at ologic reaction to th e pa tch ( 15). Other authors
have postulated a possible d esensitization procedu re for ca rba mazepine hype rsensi -
tivity reaction s ( 16). The idea of desen sitizing ca rba mazepine- ind uce d SJS patients
see ms plausible , but cons ide r ing th e somet imes fulminant a nd let ha l course of thi s
synd ro me, the ou tcome in th ese pa ti ents m ight ca r ry a far bigger ris k. Considering
th e relative benefit a nd expanded use of ca rbamazepine in psyc hia try, psychiatrist s
nee d to assess the cl inica l use of this drug on a case by case basis wi th an awa re ness of
th e associa te d adve rse reaction s.
This particul ar case was unique co nside ring th e fac t th at the pa tie nt was al so a
di abetic on glybur ide. Initiall y, a t th e manifest ation s of th e prodromal signs thi s
posed a problem of di agnosis, co ns ide r ing that glybur ide is a su lfo nylurea com pound .
Although so me cases ofSJS have been associa te d with use of so me sulphur-containing
drugs ( 17, 18), a thorough searc h fail ed to demonstrat e a case or cita tion for SJS
induced by glybur ide .
In thi s case, eve n a fte r the glybur ide was di scont inu ed and th e pa tient was
main taine d on ca rbamazepine, pr ednison e a nd hal op e r idol , the cli nica l picture
worsen ed until the carba mazepine was di scontinued . This makes a plaus ible case for
conside ring carbamazepine as th e SJS inducer. This cas e , to da te , is th e second
psyc h ia t r ic ca se of ca rba m azepine-ind uced SJS in a pat ient in th e Un ited Stat es since
t he orig inal was publish ed in 1987 (7).
Fin all y, to reduce th e incid ence of ca rbamazepine- induced SJS In psychi atric
practice , we sugges t a risk assessmen t profile approach (as used In preventive
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m edicine practice ) wh en ca rba maze pine th erapy is be ing conside re d. This enta ils
cons ide ra t ion of and application of a ll informat ion as pe rt ains to ca rba mazepine
hypersen sitivity, possible ass oc ia t ion of th e synd rom e in neurolep t ic carbam azep ine
co m bina t ions , cons ide rat ion for usin g othe r kn own a lte rnat ive to carbamazepine
with sim ila r d esired effec ts (fo r exam ple, valproic ac id). In th e end, when a d ecision is
m ad e to proceed with ca rba mazepine therapy, a more proactive approach of inquir-
ing fro m patients about sym ptoms/sig ns associa ted wit h the prodromal stage of the
synd ro me shou ld be so ug h t. In th e sa me light , th e patient sho uld be instruct ed a nd
tau ght to look ou t for sym p toms and sig ns a nd im me dia te ly in form th e sta ff to
faci lita te ea r ly intervention a nd secondary prevention of this syndrome .
REFERENCES
I. Coo mbes BW: St even s-Johnson Synd ro me ass ocia te d with Carba maze pine (T egr e tol),
Medi calJournal of Au strali a 1965; 1:895-896.
2. St rom BI, Carson JL, Halpern AC , et a l: A population-based study of St evens-J ohnson
Synd ro me. In ciden ce a nd anteced en t drug expos ur es. Archives of Derma tology 1991;
127 (6) :831-8.
3. St ro m BL, Carso n JL, H alp ern AC , e t a l: Usi ng a cla ims dat ab ase to investi gat e
drug-induced Stevens-Johnso n Synd rome . Sta t ist ics in Medi cin e 1991; 10(4):565- 76.
4. Schopf E, Stuhmer A, Rzany B, e t al: T oxic epidermal necrolysis and St even s-Johnson
Syndrome . An ep iderm iolog ic study fro m West Germany. Ar chiv es of Derma tology 199 1;
127(6) :839-'1-2.
5. T ekezaki H , Ha naoka ~1: The Use of Carbamazepine (T egreto l) in th e Co n tro l of
Ma nic-D epr essive Psychosis a nd other Manic Depressive States, C linica l Psychi atry 1971;
13:173- 183.
6. Ball enger J am es C, Post Robert M.: Carba mazepine in Ma nic Depressive Illness. A New
T reatmen t , A~lJ of Psychi a t ry 1981,July, 137:782- 790.
7. Powers NlJ & Co . (Publishers): Carbamazep ine and St even s-Johnson Synd ro me . In Psychia-
t ry Dru g Alert s. 1994 Apri l, Vol. VIII, Nu mber 4.
8. Pelekan os J , Camfield P, Gordon K: Allergic rash du e to a nt iepileptic drugs, clinica l
fea tures and managemen t. Epilepsy 1991; 3 1:554-559.
9. Bryan t BG , Matthews BL, Stev ens-Johnson syndrom e. Dru g Int ell igence and C linica l
Ph armacy 1986; 20:489-'1-93.
10. Fawcett R: Er yth em a m ultiforme major in a pat ient with ca rba maze pine . Journal of
C linica l Psychi atry 1987; 48 :4 16-+ 17.
I I. Paglia ro L, Paglia ro A: C arbamazepine -ind uced Steve ns-Johnson synd rom e. Hospita l and
Comm uni ty Psychi a t ry 1993; O cto ber, 44:999-1000.
12. Ar an a GW, Hym an SE : Psychi atric uses of ant icon vu lsant s. In Hand book of Psych ia t ric
Drug Therap y. Little Brown 108-1 27.
13. Won g KE : Stevens-johnso n Synd rom e in neurolepi ic-ca rb am azepiue combina tio n. Sin -
ga por e Med icalJou rn al 1990; O ctober, 3 1(5):432-'1-33.
14. Rod r iguez Mosquera M, Engelsias A, Sa ez A, Vidu a l C: Pat ch test di agn osis of Car-
bamaz ep ine sensit ivity. Cont act De rma tit is 1991; Au gust , 25(2): 137- 13S.
15. Va illant L, Camenen I, Lorett : Pa tch tes ting with ca rba maze pine: Reinducti on of an
exfolia te dermat itis . Archives of Derm atology 1989, 125:299.
STEVENS:J0HNSON SYNDROME 53
16. Hermie L, Spitzer ~I: Erfolgr eich e hyposen sitizat ion un gseb eh andlu mg bei ein um pa-
ti enten mit eine r schizoaffektiven Psych ose and ca rbamaze pin a lle rg ic successfu l hypose n-
sit iza t ion treatment of a patient with schizo-a ffect ive psych osis a nd ca rba maze pione
a lle rgy (t ransla t ion from German ) Nerve narzt , 1993; Ma rch , 64( 3) :208--210 .
17. Barnba MG, Eld er AT, Gray JA, Minns RA: Fatal St even s-j ohnson Synd rom e associa ted
with Iansidar and chloroq u ine,Jou rnal of Infection 1986;July, 13( I) :13.
18. Navin TR, Miller KD , Sat rial e RF , Lob el HO: Adverse reacti on s associa ted with pyrirn et h-
a rn ine -sulfadoine prophylaxis for pn eumocystis ca rinii infection s in AID S (le tt er ) Lance t
1985;June 8, 1(844 1):132.
